Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 2658083 | 4 pages | https://doi.org/10.1155/2018/2658083

Pulmonary Mucormycosis in Chronic Lymphocytic Leukemia and Neutropenia

Academic Editor: Sinésio Talhari
Received14 Sep 2017
Revised01 Jan 2018
Accepted15 Jan 2018
Published19 Feb 2018

Abstract

Pulmonary mucormycosis is a rare life-threatening fungal infection associated with high mortality. We present the case of a 61-year-old man with history of chronic lymphocytic leukemia who presented with fever and cough, eventually diagnosed with pulmonary mucormycosis after right lung video-assisted thoracoscopic surgery. The patient was successfully treated with amphotericin B and right lung pneumonectomy; however, he later died from left lung pneumonia.

1. Introduction

Pulmonary mucormycosis is a rare but life-threatening, rapidly progressive infection that occurs in immunocompromised patients with mortality as high as 76% that is 10–50 times less likely than aspergillus or candida infection [13]. Early clinical diagnosis can be delayed in the setting of concomitant infections such as pneumonia and bacteremia. However, prompt diagnosis is critical to initiate early aggressive management. We report the case of a patient with chronic lymphocytic leukemia (CLL) with resultant neutropenia undergoing chemotherapy diagnosed with pulmonary mucormycosis.

2. Case Description

A 61-year-old man with past medical history of sarcoidosis, deep vein thrombosis on rivaroxaban, and CLL treated with bendamustine and rituximab complicated by neutropenia presented to the outpatient office with (four) days of fevers and scant hemoptysis. On physical exam, patient had temperature of 38.4°C, blood pressure of 128/60 mm Hg, respirations of 18 per minute, heart rate of 92 beats per minute, and oxygen saturation of 96% in room air. Lung sounds were diminished bilaterally. His white blood cell count was 88,200/µL with absolute neutrophil count 1900/UI (2.15%), hemoglobin level 7.4 g/dL (decreased from 8.8 g/dL three weeks prior), and platelet count 291,000/µL. Chest radiograph revealed a large mass-like consolidation in the right upper lobe, which was new compared to computerized tomography (CT) imaging two months prior.

The patient was transported to the hospital, admitted for sepsis secondary to community-acquired pneumonia, and initiated on intravenous broad-spectrum antibiotics. CT chest was obtained due to concern for hemorrhage on ibrutinib. It revealed a mass-like consolidation in the right upper lobe along with diffuse nodules and multifocal airspace disease suspicious for invasive aspergillosis (Figure 1). Aspergillus antibody was obtained; however, empiric antifungal therapy was deferred while blood cultures grew S. pneumoniae. The patient failed to improve clinically prompting bronchoscopy evaluation, which identified purulent airway secretions. Bronchial aspirate cytology was unrevealing, and specimens were sent for further microbiology testing. The patient continued to decline. CT-guided needle biopsy of the consolidation established presence of scattered Gomori methenamine silver (GMS) and periodic acid-Schiff (PAS) positive structures suggestive of fungal etiology. So, voriconazole was started.

Repeat chest CT demonstrated worsening airspace disease, and the patient underwent video-assisted thoracoscopic surgery (VATS) with right upper and middle lobe wedge resection. VATS revealed severe dense adhesions, thickened and necrotic pleura, and the lung was found to be consolidated, hard, and hepatized with necrosis (Figure 2). Preliminary cultures were negative but eventually grew Rhizopus species. Since voriconazole is not effective against Rhizopus, it was discontinued and the patient was started on amphotericin B liposomal 5 mg/kg/24 hours. Six days after VATS, histopathologic analysis revealed presence of nonseptate fungal hyphae with right-angle branching suggestive of mucormycosis. Patient failed to improve after VATS; thus, patient underwent right pneumonectomy with subsequent clinical improvement. He was initially discharged to rehab eight days after pneumonectomy (43 days after admission) with plan for a 14-day course of amphotericin B after pneumonectomy followed by initiation of posaconazole as recommended per infectious disease specialist. Unfortunately, the patient returned to the hospital eleven days after discharge with complications of wound dehiscence and bronchocutaneous fistula formation that grew Rhizopus. Thus, patient’s amphotericin B course was prolonged to a total of 46 days after pneumonectomy after which he was transitioned to posaconazole. This gentleman unfortunately suffered from further wound complications, VRE infection, and was unable to return home, and discharged to a nursing facility several months later. Patient returned to the hospital from nursing home with left lung pneumonia positive for rhinovirus-enterovirus and eventually passed away seven months later due to complications during that admission.

3. Discussion

Mucormycosis can take several forms including rhinocerebral, pulmonary, cutaneous, gastrointestinal, and disseminated disease [2]. Risk factors include diabetes mellitus, hematologic malignancy, receiving hematopoietic stem cell transplant, deferoxamine therapy, injection drug use, and trauma or burns [14]. Pulmonary infection is most commonly found in patients with hematologic malignancy, as was the case in our patient [1, 2, 5]. Additional risk factors for pulmonary infection include male gender, neutropenia, chronic steroid use, underlying rheumatologic disorders, and voriconazole prophylaxis in patients undergoing chemotherapy [2, 57]. Bendamustine and rituximab have been associated with impaired lymphocyte recovery in patients with CLL, and both agents have also been associated with an increased risk of serious opportunistic infections [8, 9]. Thus, in the case of our patient, these chemotherapy agents may also have contributed to the development of mucormycosis.

The symptoms are typically nonspecific even in later stages of infection, and co-infection can further complicate diagnosis. Infection most commonly presents as acute-onset high fever with nonproductive cough, dyspnea, or chest pain that is unresponsive to broad-spectrum antibiotics [2, 4, 7].

Radiological manifestations are mostly nonspecific, and disease tends to impact the upper lobes [4]. Findings on imaging that suggest pulmonary mucormycosis are greater than ten nodules, presence of pleural effusion, and a reverse halo sign on CT chest [2, 10, 11]. Bourcier et al. found that the presence of the reverse halo sign is more common in neutropenic patients with pulmonary mucormycosis, enough for them to suggest initiation of mucormycosis antifungal therapy based on the presence of this sign [10]. Sputum secretions and broncheoalveolar lavage cultures are notoriously insensitive for detection of mucormycosis, and even cultures from fine needle aspiration often fail to grow [4, 5]. The sensitivity can be improved by placing tissue sections directly on a culture plate without prior grinding or homogenizing the material, as it can disrupt the fungal structure [4, 5]. Colonies can take three to five days to grow. Diagnosis is achieved by demonstrating hyphae with variable width (from 6 to 25 µm), zero or sparse septations, irregular ribbon-like appearance, and nonpigmented and wide-angle bifurcations including 90-degree angles. PAS and GMS stains must be used to properly visualize the hyphae [5]. Mucorales PCR has been shown to be useful for confirmation of the diagnosis of mucormycosis; however, it requires further investigation as a method of improving detection of mucormycosis in the clinical setting [12].

3.1. Management

Pulmonary mucormycosis has a poor prognosis. Patients who undergo combination of pharmacological and surgical management have been shown to do better compared to either treatment alone [4, 12, 13]. The drug of choice for initial therapy is amphotericin B while posaconazole or isavuconazole can be used for step-down therapy [14, 15]. Correction of underlying predisposing conditions, such as acidosis or neutropenia, and discontinuation of steroids or iron-chelating agents is required. Posaconazole has been reported as an effective salvage therapy in studies [14, 16]. Cornely et al. also showed that posaconazole improved survival and more effectively prevented invasive fungal infections than fluconazole or itraconazole in patients with hematologic malignancy undergoing chemotherapy [17]. Thus, to prevent severe mucor infections, posaconazole could potentially be considered for prophylaxis in patients with hematologic malignancy, especially those undergoing chemotherapy who are at risk for neutropenia.

4. Conclusion

Pulmonary mucormycosis is a rare but potentially fatal fungal infection that occurs in immunocompromised patients, most commonly in those with hematologic malignancy [1, 4]. Early recognition is crucial for prompt initiation of pharmacological and surgical comanagement to improve high rates of associated morbidity and mortality [2, 12]. Due to its nonspecific presentation, diagnosis is often difficult. However, suspicion and early initiation of therapy should be considered in immunosuppressed patients, especially neutropenic patients with hematologic malignancy, who present with fever and cough that is unresponsive to broad-spectrum antibiotics.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors appreciate the assistance of Dr. Sharon Swierczynski MD, PhD, from the Department of Pathology, for preparation and interpretation of the histology slides.

References

  1. M. M. Roden, T. E. Zaoutis, W. L. Buchanan et al., “Epidemiology and outcome of zygomycosis: a review of 929 reported cases,” Clinical Infectious Diseases, vol. 41, no. 5, pp. 634–653, 2005. View at: Publisher Site | Google Scholar
  2. G. Petrikkos, A. Skiada, O. Lortholary, E. Roilides, T. J. Walsh, and D. P. Kontoyiannis, “Epidemiology and clinical manifestations of mucormycosis,” Clinical Infectious Diseases, vol. 54, no. 1, pp. S23–S34, 2012. View at: Publisher Site | Google Scholar
  3. R. Samarei, N. Gharebaghi, and S. Zayer, “Evaluation of 30 cases of mucormycosis at a university hospital in Iran,” Mycoses, vol. 60, no. 7, pp. 426–432, 2017. View at: Publisher Site | Google Scholar
  4. F. Y. W. Lee, S. B. Mossad, and K. A. Adal, “Pulmonary mucormycosis the last 30 years,” Archives of Internal Medicine, vol. 159, no. 12, pp. 1301–1309, 1999. View at: Publisher Site | Google Scholar
  5. T. J. Walsh, M. N. Gamaletsou, M. R. McGinnis, R. T. Hayden, and D. P. Kontoyiannis, “Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis),” Clinical Infectious Diseases, vol. 54, no. 1, pp. S55–S60, 2012. View at: Publisher Site | Google Scholar
  6. G. Chamilos, E. M. Marom, R. E. Lewis, M. S. Lionakis, and D. P. Kontoyiannis, “Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer,” Clinical Infectious Diseases, vol. 41, no. 1, pp. 60–66, 2005. View at: Publisher Site | Google Scholar
  7. E. Lin, T. Moua, and A. H. Limper, “Pulmonary mucormycosis: clinical features and outcomes,” Infection, vol. 45, no. 4, pp. 443–448, 2017. View at: Publisher Site | Google Scholar
  8. R. G. Munoz, A. Izquierdo-Gil, A. Munoz, V. Roldan-Galiacho, P. Rabasa, and C. Panizo, “Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab,” Annals of Hematology, vol. 93, no. 11, pp. 1879–1887, 2014. View at: Publisher Site | Google Scholar
  9. A. Nosari, “Infectious complications in chronic lymphocytic leukemia,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, p. e2012070, 2012. View at: Publisher Site | Google Scholar
  10. J. Bourcier, P. M. Heudes, F. Morio et al., “Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003–2016),” Mycoses, vol. 60, no. 8, pp. 526–533, 2017. View at: Publisher Site | Google Scholar
  11. R. A. Murphy and W. T. Miller Jr., “Pulmonary mucormycosis,” Seminars in Roentgenology, vol. 31, no. 1, pp. 83–87, 1996. View at: Publisher Site | Google Scholar
  12. S. P. Hammond, R. Bialek, D. A. Milner, E. M. Petschnigg, L. R. Baden, and F. M. Marty, “Molecular methods to improve diagnosis and indentification of mucormycosis,” Journal of Clinical Microbiology, vol. 49, no. 6, pp. 2151–2153, 2011. View at: Publisher Site | Google Scholar
  13. M. Tedder, J. A. Spratt, M. P. Anstadt, S. S. Hegde, S. D. Tedder, and J. E. Lowe, “Pulmonary mucormycosis: results of medical and surgical therapy,” Annals of Thoracic Surgery, vol. 57, no. 4, pp. 1044–1050, 1994. View at: Publisher Site | Google Scholar
  14. J. A. Van Burik, R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis, “Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases,” Clinical Infectious Diseases, vol. 42, no. 7, pp. e61–e65, 2006. View at: Publisher Site | Google Scholar
  15. B. Spellberg, A. Ibrahim, E. Roilides et al., “Combination therapy for mucormycosis: why, what, and how?” Clinical Infectious Diseases, vol. 54, no. 1, pp. S73–S78, 2012. View at: Publisher Site | Google Scholar
  16. G. Chamilos, R. E. Lewis, and D. P. Kontoyiannis, “Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis,” Clinical Infectious Diseases, vol. 47, no. 4, pp. 503–509, 2008. View at: Publisher Site | Google Scholar
  17. O. A. Cornely, J. Maertens, D. J. Winston et al., “Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia,” New England Journal of Medicine, vol. 354, no. 4, pp. 348–359, 2007. View at: Publisher Site | Google Scholar

Copyright © 2018 Izza Mir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

833 Views | 368 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.